Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
Vinogradova Y , Coupland C , Hill T , Hippisley-Cox J 
BMJ.2018 Jul 04 ; 362():k2505.
PubMedで表示
Google翻訳で開く
(28view , 0users)
Full Text Sources
To investigate the associations between direct oral anticoagulants (DOACs) and risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality compared with warfarin.
PMID: 29973392 [PubMed - in process]
PMID: 29973392 [PubMed - in process]
関連論文
- Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
- Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
- [Review] Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis.
- Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population.
- Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.